Management of Atypical Glandular Cells and Adenocarcinoma in Situ

Obstetrics and Gynecology Clinics of North America

Volumn 35, Issue 4, 2008, Pages 623-632

  Dunton, Charles J ^a,b  

^a LANKENAU HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adenocarcinoma in situ; Atypical glandular cells; Cervical cancer screening; Cytology guidelines; Endometrial neoplasia

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADENOCARCINOMA; CANCER CYTODIAGNOSIS; CANCER RISK; CANCER SCREENING; CONDYLOMA ACUMINATUM; CYTOPATHOLOGY; DNA DETERMINATION; ENDOMETRIUM CARCINOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPANICOLAOU TEST; PREGNANCY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS CARCINOGENESIS; WART VIRUS;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POSTMENOPAUSE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 56849108555     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2008.09.002     Document Type: Review

References (49)

1. Sharpless K.E., Peter F., Schnatz P.F., et al. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 105 (2005) 494-500
2. Sharpless K.E., Schnatz P.F., Mandavilli S., et al. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol 105 (2005) 501-506 [erratum appears in Obstet Gynecol 2005;105(6):1495]
3. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 16 (2002) 2114-2119
4. Davey D.D., Neal M.H., Wilbur D.C., et al. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 128 (2004) 1224-1229
5. DeSimone C.P., Day M.E., Tovar M.M., et al. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 107 (2006) 1285-1291
6. Confortini M., Di Bonito L., Carozzi F., et al. GISCi Working Group for Cervical Cytology. Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey. Cytopathology 17 6 (2006) 353-360
7. Schnatz P.F., Guile M., O'Sullivan D.M., et al. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 107 3 (2006) 701-708
8. Chhieng D.C., Elgert P., Cohen J.M., et al. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 93 (2001) 1-7
9. Cullimore J.E., Luesley D.M., Rollason T.P., et al. A prospective study of conization of the cervix in the management of cervical intraepithelial glandular neoplasia (CIGN): a preliminary report. Br J Obstet Gynaecol 99 (1992) 314-318
10. Kim T.J., Kim H.S., Park C.T., et al. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecol Oncol 73 (2000) 292-298
11. Wright Jr. T.C., Massad L.S., Dunton C.J., et al. For the 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11 4 (2007) 201-222
12. Fetterman B., Shaber R., Pawlick G., et al. Human papillomavirus DNA testing in routine clinical practice for prediction of underlying cervical intraepithelial neoplasia 2/3+ at initial evaluation and in follow-up of women with atypical glandular cell Papanicolaou tests. J Low Genit Tract Dis 10 3 (2006) 178-179
13. Chhieng D.C., Cohen J., and Cangiarella J.F. Clinical implications of atypical glandular cells of undetermined significance, favor endometrial origin. Cancer (Cancer Cytopathol) 93 (2001) 351-356
14. Van den Bosch T., Van Schoubroeck D., Domali E., et al. A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. Ultrasound Obstet Gynecol 29 6 (2007) 674-679
15. Ioffe O.B., Sagae S., Moritani S., et al. Symposium part 3: should pathologists diagnose endocervical preneoplastic lesions "less than" adenocarcinoma in situ?. Int J Gynecol Pathol 22 (2003) 18-21
16. Wright J.D., Horowitz N.S., and Rader J.S. Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. J Reprod Med 47 11 (2002) 933-935
17. Siebers A.G., Verbeek A.L., Massuer L.F., et al. Normal appearing endometrial cells in cervical smears of asymptomatic postmenopausal women have predictive value for significant endometrial pathology. Int J Gynecol Cancer 16 (2006) 1069-1074
18. Greenspan D.L., Cardillo M., Davey D.D., et al. Endometrial cells in cervical cytology: review of cytological features and clinical assessment. J Low Genit Tract Dis 10 2 (2006) 111-122
19. Thrall M., Kjeldahl K., Gulbahce H.E., et al. Liquid-based Papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: study of 272 cases classified by the 2001 Bethesda system. Cancer 111 4 (2007) 217-223
20. Park J.Y., Kim H.S., Hong S.R., et al. Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma. J Korean Med Sci 20 1 (2005) 93-97
21. Derchain S.F., Rabelo-Santos S.H., Sarian L.O., et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 95 (2004) 618-623
22. Diaz-Montes T.P., Farinola M.A., Zahurak M.L., et al. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol 104 (2007) 366-371
23. Saqi A., Gupta P.K., Erroll M., et al. High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol 34 3 (2006) 235-239
24. de Oliveira E.R., Derchain S.F., Sarian L.O., et al. Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer 16 3 (2006) 1055-1062
25. Hunter M.I., Monk B.J., and Tewari K.S. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol 199 1 (2008) 3-9
26. Case A.S., Rocconi R.P., Straughn J.M., et al. Cervical intraepithelial neoplasia in adolescent women: incidence and treatment outcomes. Obstet Gynecol 108 6 (2006) 1369-1374
27. Ramsaroop R., and Chu I. Accuracy of diagnosis of atypical glandular cells-Conventional and ThinPrep. Diagn Cytopathol 34 9 (2006) 614-619
28. Lee K.R., Darragh T.M., Joste N.E., et al. Atypical glandular cells of undetermined significance (AGUS): interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol 117 (2002) 96-102
29. Chena S., Yanga S., Chub T., et al. Which test is a better strategy to determine the outcome of atypical glandular cell-categorized Pap smears? Immunocytochemical p16INK4A expression or human papillomavirus test-a retrospective cohort study. Gynecol Oncol 99 (2005) 578-584
30. Keating J.T., Ince T., and Crum C.P. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 8 2 (2001) 83-92
31. Liao S.Y., and Stanbridge E.J. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Cancer 88 (2000) 1108-1121
32. Boon M.E., Vinkestein A., van Binsbergen-Ingelse A., et al. Significance of MiB-1 staining in smears with atypical glandular cells. Diagn Cytopathol 31 (2004) 77-82
33. Zaino R.J. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 21 4 (2002) 314-326
34. Soutter W.P., Haidopoulos D., Gornall R.J., et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe?. BJOG 108 (2001) 1184-1189
35. Shin C.H., Schorge J.O., Lee K.R., et al. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol 79 (2000) 6-10
36. McHale M.T., Le T.D., Burger R.A., et al. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol 98 5 Pt 1 (2001) 726-731
37. Jakus S., Edmonds P., Dunton C.J., et al. Margin status and excision of cervical intraepithelial neoplasia: a review. Obstet Gynecol Surv 55 8 (2000) 520-527
38. Hopkins M.P. Adenocarcinoma in situ of the cervix-the margins must be clear. Gynecol Oncol 79 (2000) 4-5
39. Krivak T.C., Rose G.S., McBroom J.W., et al. Cervical adenocarcinoma in situ: a systematic review of therapeutic options and predictors of persistent or recurrent disease. Obstet Gynecol Surv 56 9 (2001) 567-575
40. Costa S., Negri G., Sideri M., et al. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol 106 (2007) 170-176
41. Wright Jr. T.C., Massad L.S., Dunton C.J., et al. For the 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 11 4 (2007) 223-239
42. Hwang D.M., Lickrish G.M., Chapman W., et al. Long-term surveillance is required for all women treated for cervical adenocarcinoma in situ. J Low Genit Tract Dis 8 (2004) 125-131
43. Miroshnichenko G.M., Parva M., Holtz D.O., et al. Interpretability of excisional biopsies of the cervix: cone biopsy and loop excision. J Low Genit Tract Dis 2 (2008) 152-179
44. Bryson P., Stulberg R., Shepherd L., et al. Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS?. Gynecol Oncol 93 (2004) 465-468
45. Andersen E.S., and Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol 86 (2002) 365-369
46. Lea J.S., Shin C.H., Sheets E.E., et al. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol 87 (2002) 129-132
47. Wang S.S., Sherman M.E., Hildesheim A., et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100 (2004) 1035-1044
48. Bulk S., Berkhof J., Bulkmans N.W., et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 94 (2006) 171-175
49. Ault K.A. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Obstet Gynecol Surv 61 6 Suppl 1 (2006) S26-S31